安徽华恒生物科技股份有限公司2025年度业绩快报公告

Core Viewpoint - The company, Anhui Huaheng Biotechnology Co., Ltd., reported preliminary financial data for the fiscal year 2025, indicating a significant increase in revenue but a decrease in net profit due to various market challenges and increased operational costs [1][3]. Financial Performance and Indicators - The company expects to achieve an operating income of RMB 288,579.86 million, representing a year-on-year increase of 32.50% [3]. - The net profit attributable to the parent company is projected to be RMB 13,081.59 million, reflecting a year-on-year decrease of 30.97% [3]. - The net profit after deducting non-recurring gains and losses is estimated at RMB 12,472.25 million, down 29.63% year-on-year [3]. - Total assets are expected to reach RMB 577,861.68 million, a year-on-year growth of 15.82% [3]. - The equity attributable to the parent company is projected at RMB 264,507.68 million, up 3.14% year-on-year [3]. - The estimated net asset per share is RMB 10.58, reflecting a year-on-year increase of 3.02% [3]. Factors Affecting Business Performance - The company faced a complex international environment, including anti-dumping measures in Europe and tariff policies in the U.S., which impacted its operations [4]. - The company focused on its mission to develop biotechnology and serve life health, leading to continued growth in product sales and the steady advancement of new projects [4]. - The amino acid and vitamin industries experienced a temporary supply-demand imbalance, with intense market competition affecting the average prices of key products, valine and myo-inositol, which decreased compared to the previous year [4]. - Increased operational scale led to higher expenses, contributing to the overall decline in profit [4]. Changes in Key Financial Metrics - The increase in total operating revenue is primarily attributed to higher sales volumes of amino acid products [5]. - The decrease in operating profit, total profit, and net profit attributable to the parent company is mainly due to the decline in average prices of valine and myo-inositol, along with increased operational costs [5]. - The basic earnings per share decreased, primarily due to the reduction in net profit and the increase in share capital from the third vesting period of the restricted stock incentive plan [5].